slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,539
Current window 86,101-86,130
Pages 3,685
Rows per page 30
Component
86,101-86,130 of 110,539
15
Membership Collective Group | Results Presentation Deck | 29 slidesMembership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could BeLoop · Jobs To Be Done1 hit
20
Membership Collective Group | Results Presentation Deck | 29 slidesMembership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could Be1 hit
08
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Problem Statement1 hit
20
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
21
The diagram uses a hub-and-spoke model to show iNKT cells at the center modulating innate (Dendritic, Macrophage, NK) and adaptive (T, B) cells.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
24
The diagram depicts a biological process flow involving iNKT cells, DCs, MDSCs, and inflammatory monocytes.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
26
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
28
The data shows a clear trend where the combination of iNKT activator + Fc enhanced CTLA-4 + PD-1 (Group F) results in the lowest number of metastases.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
29
The slide uses a process flow diagram to show trial progression and a list-based structure for clinical endpoints.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
30
The table displays patient characteristics (age, sex) and disposition (early discontinuation, death, progression) for three distinct dosing groups and the total population.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
31
The chart displays patient outcomes over time, with dots indicating progression and bars indicating stable disease.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
32
Includes a table of adverse events, box plots for cytokines (IL-1b, IL-6, CRP), and a longitudinal line chart for IFNy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
33
The slide uses a staircase diagram to represent dose escalation levels.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
35
The slide presents clinical trial safety data including a table of adverse events and dot plots for inflammatory markers.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
42
The diagram illustrates the interaction between iNKT cells and tumor cells/immune cells via various receptors (CAR, iTCR, NKG2D, DNAM1).Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
46
The slide uses a bar chart to show the distribution of clones, with a red circle highlighting the 'binders specific activators' category.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
47
The diagram shows the interaction between tumor cell receptors and iNKT cell receptors, including the secretion of IL15.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
49
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
50
The slide uses a Kaplan-Meier survival plot and longitudinal imaging to demonstrate therapeutic efficacy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
51
The slide uses fluorescence microscopy images and an area chart to demonstrate the efficacy of the therapy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
54
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
62
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
64
The slide uses a 'Our World in Data' chart to provide context for the mortality rates listed on the left.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
67
Clinical trial data summary table.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
69
Data presented by Saint John's Cancer Institute for MiNK Therapeutics.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
72
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
74
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
78
The slide uses a visual metaphor of a competition with a trophy to declare iNKT the winner.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
81
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
87
Uses a visual metaphor to explain biological versatility.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit